Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort

BackgroundDrug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19. Although lopinavir-ritonavir (LPV/r) and darunav...

詳細記述

書誌詳細

出版年:	Frontiers in Cellular and Infection Microbiology
主要な著者:	Dóra Paróczai, András Bikov, Andreea Blidaru, Emanuel Bobu, Ana Lascu, Cristian Ion Mot, Stefan Mihaicuta, Stefan Frent
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2025-01-01
主題:	COVID-19 darunavir lopinavir propensity score matching ritonavir
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fcimb.2024.1496176/full